217 - References

References

218 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Male smoker – target dose 375mg/day. Day Morning dose (mg) Evening dose (mg) Total daily dose (mg) – 6.25 6.25 6.25 6.25 12.5 12.5 12.5 4 12.5 37.5 25 50 25 50 25 75 25 75 50 100 50 125 75 150 75 175 100 200 100 225 125 250 125 275 150 300 150 325 175 350 175 375 References

1. Stanworth D, et al. Clozapine: a dangerous drug in a clozapine-­naive subject. Forensic Sci Int 2011; 214:e23–e25.
2. Ruan CJ, et al. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics 2020; 21:369–373.
3. Rostami-­Hodjegan A, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24:70–78.
4. Schoretsanitis G, et al. European whites may need lower minimum therapeutic clozapine doses than those customarily proposed. J Clin Psychopharmacol 2021; 41:140–147.
5. Reeves S, et al. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol 2024; 90:135–145.
6. de Leon J, et al. An international adult guideline for making clozapine titration safer by using six ancestry-­based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 2022; 55:73–86.
7. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration: a comparison of a population algorithm and three algorithms based on gene variant models. J Psychopharmacol 2023; 37:1030–1039.
8. Atkins M, et al. Haematological point of care testing for clozapine monitoring. J Psychiatr Res 2023; 157:66–71.
9. Atkins M, et al. Acceptability of point of care testing for antipsychotic medication levels in schizophrenia. Psychiatry Research Communications 2022; 2:100070.